ClinicalTrials.gg
RecruitingNCT06766526ISACUpdated Feb 24, 2025

Internet-based Support for Adjustment to Prostate Cancer

An interventional study of Internet-based cognitive behavioral therapy and Non-directive support in Psychological Distress, Depression - Major Depressive Disorder and Insomnia, sponsored by Linkoeping University. Recruiting at 1 site in Sweden. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Linkoeping University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden — 13 open to participants now, 15 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Sweden.

Planned enrollment
20th of 54
180 · median 105
Started
2025
with 4 others
No phase
42 of 58
11 open now
Primary completion
2026-06
later than 6 of 14 live
Registered
55th of 58
by date
Lead sponsor
2 of 58
Linkoeping University

Among the 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden, this one is the 20th largest by planned enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2025, is one of 42 with no phase, reaches primary completion later than 6 of the 14 other live ones, and was the 55th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

13 of the 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Sleep Initiation and Maintenance Disorders with a site in Sweden, or all of them as a file.
02

Study summary

The study aims to study the efficacy of internet-based cognitive behavior therapy (ICBT) in reducing subjective distress and comorbid psychiatric symptoms in men diagnosed with prostate cancer. Participants who have been diagnosed with prostate cancer and are currently not undergoing or scheduled to undergo medical treatment will be recruited. Once recruited, they will be randomized to receive either a tailored, eight-week long ICBT intervention or an attention control group. Both group receive weekly support by a trained therapist.

Read the detailed description

Men diagnosed with prostate cancer frequently suffer from a wide range of psychological problems that can be traced to their disorder. Examples include depressed mood and worry regarding the prognosis and/or cancer recurrence. Psychological treatments can be used for helping cancer patients deal with this kind of distress, but frequently only targets one kind of symptoms.

This study investigates a tailored approach to providing help for men diagnosed with prostate cancer. Participants randomized to the treatment condition will receive an eight week ICBT intervention which is tailored to the problem profile of the participant in question. The treatment will last eight weeks and participants will receive weekly support and feedback from a therapist. Participants randomized to the control condition will receive weekly therapist support, but not access to the treatment modules. The primary outcome of interest is psychological distress, and other health-related outcomes will be measured as well. Participants will be recruited in Sweden with a nationwide recruitment.

03

Conditions studied

  • Psychological Distress
  • Depression - Major Depressive Disorder
  • Insomnia
  • Anxiety
  • Prostate Cancer

Keywords

  • Psychological distress
  • Prostate cancer
  • Cancer
  • ICBT
  • Cognitive behavior therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjectively reported psychological symptoms and problems that have come about after a prostate cancer diagnosis.
  • A sum score above 19 on the primary outcome measure (Kessler-10).
  • An age of 18 or older.
  • Ability to speak, read, and write Swedish.
  • Access to a computer/laptop/tablet/smartphone and internet access.
  • Sufficient computer profiency to be able to use the treatment platform.

Exclusion criteria

Exclusion Criteria:

  • Planned medical treatment or planned change in medication related to the prostate cancer during the treatment period.
  • Recently finished (within the past six months) medical treatment for prostate cancer.
  • Severe psychiatric or somatic conditions that impedes participation in the study.
  • Ongoing substance use problems.
  • Acute suicidality.
  • Other ongoing psychological treatment.
  • Psychopharmaceutic treatment that has been changed within the past month or with planned changes during the treatment phase.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Tailored ICBT

    An eight week long ICBT treatment that is tailored to the problem profile of the participant. The treatment is modular, with one module being administered per week of the treatment.

    Behavioral: Internet-based cognitive behavioral therapy

  • Active comparator
    Non-directive support

    The control group will receive weekly support via contact with a therapist, without receiving access to the treatment modules.

    Behavioral: Non-directive support

Interventions

  • BehavioralInternet-based cognitive behavioral therapy

    An eight week ICBT treatment. The treatment is modular and tailored to the problem profile of the participant. One module will be administered every week during the treatment phase.

  • BehavioralNon-directive support

    Participants randomized to this condition will receive weekly support and contact with a therapist via the treatment platform. They will not have access to the treatment modules during the treatment phase.

06

What researchers measure

Primary outcomes

  1. Kessler-10 (K10)

    Measure of psychological distress. Consists of 10 items. Higher scores indicate greater psychological distress. Scores can range between 10 and 50.

    Time frame: At pretreatment, weekly during the treatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

Secondary outcomes

  1. Fear of Cancer Recurrence Inventory, short form (FCRI)

    Measure of fear of the cancer recurring and/or spreading. Consists of 9 items. Higher scores indicate greater fear/anxiety levels. Scores can range between 0 and 36.

    Time frame: At pretreatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

  2. Generalized Anxiety Disorder-7 item scale (GAD-7)

    Measure of symptoms of generalized anxiety disorder. Consists of seven items. Higher scores indicate greater anxiety. Scores can range between 0 and 21.

    Time frame: At pretreatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

  3. Insomnia Severity Index (ISI)

    Measure of insomnia and sleep related-difficulties. Consists of seven items. Higher scores indicate greater sleep related-difficulties. Scores can range from 0 to 28.

    Time frame: At pretreatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

  4. Brunnsviken Brief Quality of Life Scale (BBQ)

    Measure of quality of life. Consists of 12 items. Higher scores indicate a greater quality of life. Scores can range between 0 and 96.

    Time frame: At pretreatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

  5. The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30)

    Measure of health-related quality of life. Consists of 30 items and three main subscales which each will serve as an outcome: Global health status, Functional status, and Symptom status. Higher scores indicate a greater health status within the domain. Scores can range between 0 and 100.

    Time frame: At pretreatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

  6. The Illness Cognition Questionnaire (ICQ)

    Measure of cognitions about the illness (in this case prostate cancer). Consists of 18 items. Analyzed separately as three subscales: Acceptance, Perceived benefits, and Helplessness. Greater scores indicate greater acceptance, more perceived benefits, and greater helplessness, respectively. Will also be used as mediators in a mediation analysis with the rate of change in subscale sum scores used as mediators. Sum scores for each subscale can range between 6 and 24.

    Time frame: At pretreatment, weekly during the treatment, after nine weeks, six months after completion of treatment, and twelve months after completion of treatment.

Other outcomes

  1. Client Satisfaction Questionnaire-8 item version (CSQ-8)

    Measure of treatment satisfaction. Consists of eight items. Higher scores indicate greater treatment satisfaction. Scores can range between 8 and 32.

    Time frame: Measured after nine weeks of treatment.

07

Study locations

1 of 1 sites recruiting
  • Department of Behavioral Sciences and Learning
    Linköping, 58183, Sweden
    Recruiting
    • Gerhard Andersson, Ph.D. · Contactgerhard.andersson@liu.se · +46-13285840
    • Gerhard Andersson, Ph.D. · Principal investigator
    • Anton Käll, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jun 2026, 17 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 17 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 9, 2025
StartActual
Jan 5, 2025
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06766526
Responsible party
Gerhard Andersson (Professor, Linkoeping University) — Principal investigator
First posted
Jan 9, 2025
Start date
Jan 5, 2025
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 24, 2025

Study contacts

Gerhard Andersson, Ph.D.
Contact
gerhard.andersson@liu.se
+46-13285840
Anton Käll, Ph.D.
Contact
anton.kall@liu.se
Gerhard Andersson, pHD
principal investigator · Linkoeping University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion